Literature DB >> 27605875

Hepatitis C virus: Promising discoveries and new treatments.

Juliana Cristina Santiago Bastos1, Marina Aiello Padilla1, Leonardo Cardia Caserta1, Noelle Miotto1, Aline Gonzalez Vigani1, Clarice Weis Arns1.   

Abstract

Despite advances in therapy, hepatitis C virus (HCV) infection remains an important global health issue. It is estimated that a significant part of the world population is chronically infected with the virus, and many of those affected may develop cirrhosis or liver cancer. The virus shows considerable variability, a characteristic that directly interferes with disease treatment. The response to treatment varies according to HCV genotype and subtype. The continuous generation of variants (quasispecies) allows the virus to escape control by antivirals. Historically, the combination of ribavirin and interferon therapy has represented the only treatment option for the disease. Currently, several new treatment options are emerging and are available to a large part of the affected population. In addition, the search for new substances with antiviral activity against HCV continues, promising future improvements in treatment. Researchers should consider the mutation capacity of the virus and the other variables that affect treatment success.

Entities:  

Keywords:  Antiviral research; Hepatitis C infection; Hepatitis C virus; Treatments

Mesh:

Substances:

Year:  2016        PMID: 27605875      PMCID: PMC4968121          DOI: 10.3748/wjg.v22.i28.6393

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  83 in total

1.  The error threshold.

Authors:  Christof K Biebricher; Manfred Eigen
Journal:  Virus Res       Date:  2005-02       Impact factor: 3.303

Review 2.  Therapy of hepatitis C: overview.

Authors:  K L Lindsay
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

Review 3.  Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies.

Authors:  Salvatore Petta; Marcello Maida; Fabio Salvatore Macaluso; Marco Barbara; Anna Licata; Antonio Craxì; Calogero Cammà
Journal:  Gastroenterology       Date:  2015-09-18       Impact factor: 22.682

4.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

Review 5.  Hepatitis C virus genetic variability in patients undergoing antiviral therapy.

Authors:  Juan Cristina; María del Pilar Moreno; Gonzalo Moratorio
Journal:  Virus Res       Date:  2007-04-20       Impact factor: 3.303

6.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

Authors:  Eric Lawitz; Mark S Sulkowski; Reem Ghalib; Maribel Rodriguez-Torres; Zobair M Younossi; Ana Corregidor; Edwin DeJesus; Brian Pearlman; Mordechai Rabinovitz; Norman Gitlin; Joseph K Lim; Paul J Pockros; John D Scott; Bart Fevery; Tom Lambrecht; Sivi Ouwerkerk-Mahadevan; Katleen Callewaert; William T Symonds; Gaston Picchio; Karen L Lindsay; Maria Beumont; Ira M Jacobson
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

Review 7.  The nature of interferon-alpha resistance in hepatitis C virus infection.

Authors:  Jean-Michel Pawlotsky
Journal:  Curr Opin Infect Dis       Date:  2003-12       Impact factor: 4.915

8.  Potential market size and impact of hepatitis C treatment in low- and middle-income countries.

Authors:  M E Woode; M Abu-Zaineh; J Perriëns; F Renaud; S Wiktor; J-P Moatti
Journal:  J Viral Hepat       Date:  2016-02-29       Impact factor: 3.728

Review 9.  Genetic diversity and evolution of hepatitis C virus--15 years on.

Authors:  Peter Simmonds
Journal:  J Gen Virol       Date:  2004-11       Impact factor: 3.891

10.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

View more
  6 in total

1.  The spectrum of histopathological findings after SVR to DAA for recurrent HCV infection in liver transplant recipients.

Authors:  Vedha Sanghi; Carlos Romero-Marrero; Gianina Flocco; Rondell P Graham; Baraa Abduljawad; Fadi Niyazi; Mohammad M Asfari; Koji Hashimoto; Bijan Eghtesad; K V Narayanan Menon; Federico N Aucejo; Rocio Lopez; Lisa M Yerian; Daniela S Allende
Journal:  Virchows Arch       Date:  2021-09-08       Impact factor: 4.064

2.  Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in HCV GT2.

Authors:  Ernest Asante-Appiah; Paul Ingravallo; Patricia McMonagle; Karin Bystol; Ellen Xia; Stephanie Curry; Ping Qiu; Stuart Black; Robert Chase; Rong Liu; Fred Lahser
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

3.  Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.

Authors:  Ernest Asante-Appiah; Stephanie Curry; Patricia McMonagle; Paul Ingravallo; Robert Chase; David Nickle; Ping Qiu; Anita Howe; Frederick C Lahser
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.938

4.  Lurking epidemic of hepatitis C virus infection in Iran: A call to action.

Authors:  Reza Taherkhani; Fatemeh Farshadpour
Journal:  World J Hepatol       Date:  2017-08-28

Review 5.  The Roles of Matricellular Proteins in Oncogenic Virus-Induced Cancers and Their Potential Utilities as Therapeutic Targets.

Authors:  Naoyoshi Maeda; Katsumi Maenaka
Journal:  Int J Mol Sci       Date:  2017-10-21       Impact factor: 5.923

6.  Host immune response in chronic hepatitis C infection: involvement of cytokines and inflammasomes.

Authors:  Mihail Virgil Boldeanu; Isabela Siloşi; Andreea Lili Bărbulescu; Raluca Elena Sandu; Cristiana Geormăneanu; Vlad Pădureanu; Mircea Vasile Popescu-Drigă; Ioan Sabin Poenariu; Cristian Adrian Siloşi; Anca Marilena Ungureanu; Anda Lorena Dijmărescu; Lidia Boldeanu
Journal:  Rom J Morphol Embryol       Date:  2020       Impact factor: 1.033

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.